Bli medlem
Bli medlem

Du är här


Orion Oyj: Publishing of Orion Corporation's Interim Report for January-March 2015 on 29 April 2015


Publishing of Orion Corporation's Interim Report for January-March 2015 on 29
April 2015

Orion will publish its Interim Report for January-March 2015 on Wednesday, 29
April 2015 approximately at 12:00 noon Finnish time (EEST). The release and
related presentation material in Finnish and in English will be available on
the Group's homepage after the

News conference for analysts and mediaA news conference for analysts and media will be held on Wednesday 29 April
2015 at 13:30 EEST at Hotel Kämp,
address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will
give a brief presentation in English on the financial review. Questions can
be asked after the result presentation.

Participants should be prepared to present a photo ID on request.

Live webcast and conference callA link to the live webcast will be available at Orion's

The conference call ID is 952732 and the phone numbers to participate the
conference are:

Finland: +358 (0)9 2313 9201
Sweden: +46 (0)8 5052 0110
UK: +44 (0)20 7162 0077
USA: +1 334 323 6201

News conference recordingsA recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

Silent periodThe silent period preceding the publication is ongoing and continues until the

Orion Corporation

| Timo Lappalainen Jari Karlson |
|President and CEO |
| CFO |

Orion Corporation
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. The core therapy areas of Orion's pharmaceutical
R&D are central nervous system (CNS) disorders, oncology and respiratory for
which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.